TNBC and hormone receptor (HR)-negative/HER2-positive (HR-/HER2+) breast cancers show higher lymphocytic infiltrates compared to HR+ breast cancers, and increased TIL scores were associated with higher pathological complete response (pCR) rates to neoadjuvant chemotherapy [4,5,6,7,8,9,10]. The gene discussed is NR4A1; the disease is breast carcinoma.